Combretastatin A4

For research use only.

Catalog No.S7783

2 publications

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 M1rrUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDTT21GVC13IH3lcIFvd22jIHPlcIwhdGmwZYOsJGVFPTB;Mz6wNGUuODhizszN NH3WW5EyQDd3M{Ww
A-549 NIXnTpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFLCU|dEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBCNTV2OTDseY5oKGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwMkDFMVA3KM7:TR?= MUOxPFc2OzVy
MCF-7 MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;wR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWNHNTdiYoLlZZN1KGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTNwOEDFMVA3KM7:TR?= MnrQNVg4PTN3MB?=
HT-29 MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDIWE0zQSClb3zvckBi\GWwb3PhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUGuNlBGNTB4IN88US=> M170clE5PzV|NUC=
MLM melanoma cell NX3EeYUxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1XsUmN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1NVSCvZXzhco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwNEDFMVA3KM7:TR?= M{P5V|E5PzV|NUC=
M14 NInsUYFEgXSxdH;4bYNqfHliYYPzZZk> MYPJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KHSnc4Tl[EBi\2GrboP0JIh2dWGwIH3lcIFvd22jIHPhcoNmeiBqTUG0LUBk\WyuIHzpcoUtKEeLNUC9NE4xODBzIN88US=> M1PGSlEzPzJ7NkSw
SK-OV3 NVnmOGdwS3m2b4TvfIlkcXS7IHHzd4F6 NEP5b5ZKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhfGW|dHXkJIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIhMFONLV;WN{kh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> MX6xNlczQTZ2MB?=
HL60 cells M37rN2N6fG:2b4jpZ4l1gSCjc4PhfS=> NHzObnc4OiCq NWjuS|hsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByMTFOwG0> M13Fc|IxPzNzM{W1
SK-OV-3 NHrTOodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\EOFghcA>? NFjiWJpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFAyOyEQvF2= Mk[xNVg4OjJzMke=
HepG2 cells MWjDfZRwfG:6aXPpeJkh[XO|YYm= Mon3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEmFNUC9NE4xODBzNDFOwG0> NEfzR3IyPzF{N{C2NS=>
ZR-75-1 NF7ZSHhEgXSxdH;4bYNqfHliYYPzZZk> NIXERmdEgXSxdH;4bYNqfHliYXfhbY5{fCCcUj23OU0yKGOnbHygcIlv\SxiSVO1NF0xNjByMEK0JO69VQ>? M4\KUlE4OjR7NkS5
HeLa cell NYjiXnR{S3m2b4TvfIlkcXS7IHHzd4F6 M{fDR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEinTHGgZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOyEQvF2= NWewUpRNOTd{NEm2OFk>
HCT116 cell NFjHcHhEgXSxdH;4bYNqfHliYYPzZZk> M2Ta[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiFVEGxOkBk\WyuIHzpcoUtKEmFNUC9NE4xODB|NTFOwG0> MWSxO|I1QTZ2OR?=
KBV1 cells NHLmW|BEgXSxdH;4bYNqfHliYYPzZZk> NEToOpI4OiCq Mn:2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6geolv[myjc4TpcoUuemW|aYP0ZY51KEuEVkGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMESg{txO M1voT|IxPzNzM{W1
SKOV3 M2HU[2N6fG:2b4jpZ4l1gSCjc4PhfS=> NF;yWlVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA1OiEQvF2= M2fMdFI1ODF4MECy
SKOV3 cells M{DPUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN MUiyN|c4OjNyOR?=
HeLa cells MXHDfZRwfG:6aXPpeJkh[XO|YYm= NEjDSYtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFUyKM7:TR?= MnLENVk5Pzl5NUi=
DU145 cells M{PwUWN6fG:2b4jpZ4l1gSCjc4PhfS=> MnvRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOVQh|ryP M2DDclI1ODF4MECy
DU145 cells MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUXaO2d4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMEW0JO69VQ>? M162VlI{Pzd{M{C5
SK-N-BE NH7CeoxRem:uaX\ldoF1cW:wIHHzd4F6 NYL4TXhpPzJiaB?= MnvqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gV2suVi2ERTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByNUig{txO NYnYcY1rOjJ|Mkm1OlE>
NCIH460 cells M3fHOGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1rDclQ5KGh? NYXRV3h2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLSES2NEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOkDPxE1? MXmxPFMxOzh2OR?=
KB-VIN10 cells M{jwOHBzd2yrZnXyZZRqd25iYYPzZZk> NWX0O2NiPzJiaB?= NEmye|ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP Mlv4NlE3PDF5MEC=
HCT116 cells MojBR5l1d3SxeHnjbZR6KGG|c3H5 M1fuN|czKGh? MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMEe0JO69VQ>? MlX0NlE6PTV2NUS=
DU145 cells NECyfJVEgXSxdH;4bYNqfHliYYPzZZk> MnPROFghcA>? Mm\4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxODhizszN M{L6OlE5OzB|OES5
RS4:11 cells MVnQdo9tcW[ncnH0bY9vKGG|c3H5 M3rZNFczKGh? NX7FN4tGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSV|Q7OTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JEg{NSh2LEWt[Ilu\XSqeXz0bIligm:uLUKtfYwqNTJuNT3kbZBp\W67bITleJJigm:uaYXtJIJzd22rZHWgeIV{fCxiSVO1NF0xNjByMEig{txO NFPyPXAzPTd6NU[wOS=>
HCT 116 NWnC[YhGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX7Dc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= MWGxNVcyPDZzMx?=
HeLa cells MXTDfZRwfG:6aXPpeJkh[XO|YYm= NYDPdm9DPzJiaB?= NULUcpJ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA4OiCqcoOgZpkhemW|YYr1dolvKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2wMlAxODlizszN NEf2eGkzPDZ4OUi4PC=>
BNL 1ME A.7R.1 cells MkT3R5l1d3SxeHnjbZR6KGG|c3H5 NH3jZmJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDVkxiMV3FJGEvP1JwMTDj[YxteyxiSVO1NF0xNjByMEmg{txO M1yxVlI2Pzh3NkC1
Calu6 MWLQdo9tcW[ncnH0bY9vKGG|c3H5 M2npTVQ5KGh? MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjbIW2JIFnfGW{IES4JIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eTygTWM2OD1yLkCwNFk1KM7:TR?= NVzGbJFsOjF5N{S0PVk>
melanoma B16 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1jBcGNwdmOnboTyZZRqd25id3jpZ4gheHKxZIXj[ZMhPTBnIHnubIljcXSrb36gc4Yh\3Kxd4ToJI9nKG23cnnu[UBu\Wyjbn;tZUBDOTZiY3XscEBtcW6nLDDJR|UxRTBwMECxJO69VQ>? M1TVdVEyPzF2NkGz
DU145 cells NUnHeZA3S3m2b4TvfIlkcXS7IHHzd4F6 M2OxUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MVGyNFQ6Pjl{Mx?=
HCT116 cells MljBVJJwdGmoZYLheIlwdiCjc4PhfS=> Mk\3O|IhcA>? M4\JOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MWSyNVEyOjF|MB?=
HCT15 cells NXXKWYJ{WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIfXSmQ4OiCq M2fZd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? M2XDSVIyOTF{MUOw
HL60 cells NIrZOYFRem:uaX\ldoF1cW:wIHHzd4F6 NYOyNol{PzJiaB?= MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MmizNlE3PjN|MUm=
A10 cells NWPzd2M5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3fqZ|Q5KGh? MYXHdo94fGhiaX7obYJqfGmxbjDv[kBz[XRiQUGwJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NUjOc4JrOjJyNESxOlQ>
HUVEC cells M3zvWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVy0PEBp M33TeWdzd3e2aDDpcohq[mm2aX;uJI9nKEiXVlXDJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MViyNlA1PDF4NB?=
HL60 cells NUn6TVVSS3m2b4TvfIlkcXS7IHHzd4F6 MW[3NkBp NFi2UFdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MX6yNlE{PjNzMh?=
HL60 cells M3LPXXBzd2yrZnXyZZRqd25iYYPzZZk> NIrzdZo4OiCq M3:0OGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M3jCclIzPTd6MUGx
NCI-H522 cells MmLxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4LPc|Q5KGh? M2XlRWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO MkK5NlI6QDJzMkK=
MDA-MB-435 cells MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPlU|Q1QCCq M3u0N2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M1XCZlIzQTh{MUKy
OVCAR3 MnLUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmTGOFghcA>? NF7JXo5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQXkODUkOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> Mo[wNlI6QDJzMkK=
NCI/ADR-RES cells NG\vNYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjVOFghcA>? NGrHSZlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NW\qNY12OjJ7OEKxNlI>
PC3 cells MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWLhSZVTPDhiaB?= MkSxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP MXSyNlk5OjF{Mh?=
DU145 cells MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rZTVQ5KGh? M1HzSWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NWHBdJpyOjJ7OEKxNlI>
MDA-MB-231 cells M{DGXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFnwVm01QCCq NH3BeohIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP NHeyNVczOjl6MkGyNi=>
CEM cells MlzYR5l1d3SxeHnjbZR6KGG|c3H5 MUm3NkBp NGTnSWJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NFvUZ3czOjZ5NkK0Oy=>
HCT116 cells MkLUR5l1d3SxeHnjbZR6KGG|c3H5 M1LLOlczKGh? M1fvXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> NHHUOIkzOjZ5NkK0Oy=>
MDA-MB-435 cells NE\IW2xEgXSxdH;4bYNqfHliYYPzZZk> MVq3NkBp NVvQXJpWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MUKyNlY4PjJ2Nx?=
HaCaT cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 NWLtPJVUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIZWNiXCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NGLuXXYzOzB4M{SwNS=>
HL60 cells NEfLdZNRem:uaX\ldoF1cW:wIHHzd4F6 MlrCO|IhcA>? MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> M2KyOFI{OTF5MUex
HL60 cells MlSxVJJwdGmoZYLheIlwdiCjc4PhfS=> MoLHO|IhcA>? MkLnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSBqMz2oOEw2NWSrbXX0bJltfGirYYrvcE0zNXmuKT2yMFUu\GmyaHXufYx1\XS{YYrvcIl2dSCkcn;tbYRmKHSnc4SsJGlEPTB;MD6wNFEh|ryP M4nleVI2Pzh3NkC1
HT-29 NXvINZEzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUns[5FzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MljDNlU3QDlzMUG=
HL60 cells NUHReJFiWHKxbHnm[ZJifGmxbjDhd5NigQ>? M{fGcFczKGh? M13LbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NEXHN2QzODR{MESzPS=>
Hs578T cells MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHLWJhMPDhiaB?= NI\BPY5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJezV5OGSgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NU\I[nFMOjJ7OEKxNlI>
HL60 cells MlHJR5l1d3SxeHnjbZR6KGG|c3H5 M2nKPVczKGh? NWXoNVlMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> M3vUflI{PDR3NEm2
SKOV3 cells MmfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfqVXZ7T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M{XDclI2Pjh7MUGx
MDA-MB-468 cells MXnDfZRwfG:6aXPpeJkh[XO|YYm= MkHPOEBl[Xm| NH:5TVNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IESg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEyKM7:TR?= NXnUflVYOjR{MUC1NFM>
MCF7 cells NYfydodIWHKxbHnm[ZJifGmxbjDhd5NigQ>? M{LTdlczKGh? NXrMT|dYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzMUGg{txO MV2yNlMzQTV4MR?=
H460 M1:5PWN6fG:2b4jpZ4l1gSCjc4PhfS=> Mln2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKHSnc4SsJGlEPTB;MD6wNFEzKM7:TR?= NHK0foYyQDd6M{KwOy=>
H460 M3;aW3Bzd2yrZnXyZZRqd25iYYPzZZk> NFG0e5hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOsJGlEPTB;MD6wNFEzPCEQvF2= NUTw[nVsOTZ5MkK2N|M>
NCI-H460 cells MmTBR5l1d3SxeHnjbZR6KGG|c3H5 Mni2O|IhcA>? NE\KeolEgXSxdH;4bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkB1\XO2LDDJR|UxRTBwMECxN{DPxE1? NYjK[5h1OTh|OU[4OVc>
OVCAR8 cells NEftSVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXrNTVM5QTZiaB?= MX7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPWmNCWjhiY3XscJMhd3[ncnX4dJJme3OrbnegVE1odHmlb4Dyc5RmcW5iYX\0[ZIhQTZiaILzMEBKSzVyPUCuNFAyOyEQvF2= Mnz6NlIxPDRzNkS=
NCI/ADR-RES cells M1XZcGN6fG:2b4jpZ4l1gSCjc4PhfS=> NIDJcpREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= NXywOnRMOjN{MUS0OVI>
OVCAR8 cells MYXDfZRwfG:6aXPpeJkh[XO|YYm= MUO5OkBp NH3vfoNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkigZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiOU[gbJJ{KGK7IFfp[Y1{[SC|dHHpcolv\y2kYYPl[EBtcWeqdDDtbYNzd3Olb4D5MEBKSzVyPUCuNFAyOyEQvF2= NXvzSIU1OjVyMkW5PVE>
NCI/ADR-RES cells NFOxNIxEgXSxdH;4bYNqfHliYYPzZZk> NWjxdVAxQTZiaB?= MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC5OkBpenNiYomgS4lmdXOjIIP0ZYlvcW6pLXLhd4VlKGyrZ3j0JI1q[3Kxc3PvdJktKEmFNUC9NE4xODF|IN88US=> NHnXUGczPTB{NUm5NS=>
OVCAR8 cells NGDXZVhEgXSxdH;4bYNqfHliYYPzZZk> NG\lW5FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkigZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCLQ{WwQVAvODBzMzFOwG0> M{DTblI{OjF2NEWy
HuTu 80 cells MoW3VJJwdGmoZYLheIlwdiCjc4PhfS=> MkDZO|IhcA>? NX3wSlk4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hUHWWdTC4NEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxN|ch|ryP NULnRoFZOjJ|Mkm1OlE>
K562 cells MXnDfZRwfG:6aXPpeJkh[XO|YYm= MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUCuNFAyPCEQvF2= MlHtNVk5Ozd3OUS=
NCI/ADR (MDR) cells Mn\WSpVv[3Srb36gZZN{[Xl? MlLOR4VtdCCleXPs[UBienKnc4SgbY4hVkOLL1HEVkApVUSUKTDj[YxteyCkeTDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTygTWM2OD1yLkCwNVUh|ryP NXmxfZlSOTZ|N{exPFc>
HUVEC M{\QWXBzd2yrZnXyZZRqd25iYYPzZZk> MlLrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{whUUN3ME2wMlAxOTVizszN MXuxOlczOjZ|Mx?=
KB cell MnvuVJJwdGmoZYLheIlwdiCjc4PhfS=> NUPnbWl{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuIHzpcoUh[nlibXX0bJlt\W6nIHLseYUh\HmnIHHzd4F6NCCLQ{WwQVAvODBzNTFOwG0> M4DvXlE4ODN2MUS3
KB-VIN10 cell MX\Qdo9tcW[ncnH0bY9vKGG|c3H5 MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHygcIlv\SCkeTDt[ZRpgWynbnWgZox2\SCmeXWgZZN{[XluIFnDOVA:OC5yMEG1JO69VQ>? MmDtNVcxOzRzNEe=
Human SH-SY5Y neuroblastoma cells NF;oNZVHfW6ldHnvckBie3OjeR?= MkPETY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiSIXtZY4hW0hvU2m1XUBv\XW{b3LsZZN1d22jIHPlcIx{NCCLQ{WwQVAvODBzNTFOwG0> MkGxNVU6PjN5MkK=
SW620 cells NVTXTGxYWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4HWd|czKGh? MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyPTJizszN MXmyNlMzQTV4MR?=
Molt4/C8 cells NHPGZVRRem:uaX\ldoF1cW:wIHHzd4F6 NUnWd4JMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNc4x1PC:FODDj[YxteyxiSVO1NF0xNjByMU[g{txO NH;2RYwyPzB|NEG1NC=>
ACHN cell NUHqelNlWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mle0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDkdpVoKHKnc3nzeIFvfCCDQ1jOJINmdGxibHnu[UBmgHC{ZYPzbY5oKE2GUkGgZpkhSWyjbXHyJGJtfWViYYPzZZktKEmFNUC9NE4xODF4IN88US=> M{m4e|E4Ojh4M{mz
Molt4/C8 cells MVXQdo9tcW[ncnH0bY9vKGG|c3H5 NWrhTWFYOyCmYYnz MWHBcpRqeHKxbHnm[ZJifGm4ZTDl[oZm[3RiYXfhbY5{fCCqdX3hckBOd2y2ND;DPEBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUC9NE4xODF4IN88US=> MUmxO|QyQTZyNx?=

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID